SGN-CD70A is an antibody-drug conjugate targeted to CD70, which is expressed in renal cell carcinoma and hematologic malignancies. SGN-CD70A employs our newest proprietary ADC technology. This technology comprises a potent cell-killing agent called a pyrrolobenzodiazepine (PBD) dimer that works by a different mechanism than auristatins. The PBD dimer is stably linked to an antibody with our site-specific engineered cysteines, resulting in uniform drug-loading of two PBD dimers per antibody. We call this engineered antibody an EC-mAb.
SGN-CD70A is being evaluated in a phase 1 clinical trial for patients with renal cell carcinoma.